China Dasheng Biotechnology Company
Cycclone Inc., together with its subsidiaries, engages in the production, marketing, and distribution of bacteria based products used as additives for livestock feed and crop cultivation in the People's Republic of China. It provides artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends; and biological preservatives. The company offers AM/HM bacte… Read more
China Dasheng Biotechnology Company (CDBT) - Total Assets
Latest total assets as of December 2024: $420.22K USD
Based on the latest financial reports, China Dasheng Biotechnology Company (CDBT) holds total assets worth $420.22K USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
China Dasheng Biotechnology Company - Total Assets Trend (2006–2023)
This chart illustrates how China Dasheng Biotechnology Company’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
China Dasheng Biotechnology Company - Asset Composition Analysis
Current Asset Composition (June 2023)
China Dasheng Biotechnology Company's total assets of $420.22K consist of 26.4% current assets and 73.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2023)
This chart illustrates how China Dasheng Biotechnology Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Dasheng Biotechnology Company's current assets represent 26.4% of total assets in 2023, a decrease from 74.4% in 2006.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2023, down from 14.6% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
China Dasheng Biotechnology Company Competitors by Total Assets
Key competitors of China Dasheng Biotechnology Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $281.56 Million |
|
Azure Holding Group Corp
PINK:AZRH
|
USA | $16.92 Million |
|
Constellation Capital Corp.
V:CNST-P
|
Canada | CA$627.53K |
|
Little Fish Acquisition I Corp.
V:LILL-P
|
Canada | CA$56.48K |
|
Hana 30 Special Purpose Acquisition Company
KQ:469880
|
Korea | ₩17.89 Billion |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
China Dasheng Biotechnology Company - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - China Dasheng Biotechnology Company generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - China Dasheng Biotechnology Company is currently not profitable relative to its asset base.
China Dasheng Biotechnology Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.10 | 0.06 | 0.62 |
| Quick Ratio | 0.10 | 0.06 | 0.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.06 Million | $ -1.90 Million | $ -19.47K |
China Dasheng Biotechnology Company - Advanced Valuation Insights
This section examines the relationship between China Dasheng Biotechnology Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.47 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $476.97K |
| Market Capitalization | $559.38 USD |
Valuation Analysis
Below Book Valuation: The market values China Dasheng Biotechnology Company's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: China Dasheng Biotechnology Company's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for China Dasheng Biotechnology Company (2006–2023)
The table below shows the annual total assets of China Dasheng Biotechnology Company from 2006 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-06-30 | $476.97K | -- |
| 2022-06-30 | $0.00 | -- |
| 2008-06-30 | $20.25 Million | +185878.34% |
| 2007-10-31 | $10.89K | -99.93% |
| 2007-06-30 | $15.39 Million | +31430.54% |
| 2006-06-30 | $48.81K | -- |